These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21120554)

  • 21. Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1.
    Jerabek P; Martinek V; Stiborova M
    Neuro Endocrinol Lett; 2012; 33 Suppl 3():25-32. PubMed ID: 23353840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural and energetic analysis to provide insight residues of CYP2C9, 2C11 and 2E1 involved in valproic acid dehydrogenation selectivity.
    Bello M; Mendieta-Wejebe JE; Correa-Basurto J
    Biochem Pharmacol; 2014 Jul; 90(2):145-58. PubMed ID: 24794636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Theoretical study of the ligand-CYP2B4 complexes: effect of structure on binding free energies and heme spin state.
    Harris DL; Park JY; Gruenke L; Waskell L
    Proteins; 2004 Jun; 55(4):895-914. PubMed ID: 15146488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Site of metabolism prediction on cytochrome P450 2C9: a knowledge-based docking approach.
    Tarcsay A; Kiss R; Keseru GM
    J Comput Aided Mol Des; 2010 May; 24(5):399-408. PubMed ID: 20361237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Importance of hydrophobic parameters in identifying appropriate pose of CYP substrates in cytochromes.
    Ramesh M; Bharatam PV
    Eur J Med Chem; 2014 Jan; 71():15-23. PubMed ID: 24269512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of the decrease in catalytic activity of human cytochrome P450 2C9 polymorphic variants investigated by computational analysis.
    Sano E; Li W; Yuki H; Liu X; Furihata T; Kobayashi K; Chiba K; Neya S; Hoshino T
    J Comput Chem; 2010 Nov; 31(15):2746-58. PubMed ID: 20839301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantum mechanics/molecular mechanics modeling of regioselectivity of drug metabolism in cytochrome P450 2C9.
    Lonsdale R; Houghton KT; Żurek J; Bathelt CM; Foloppe N; de Groot MJ; Harvey JN; Mulholland AJ
    J Am Chem Soc; 2013 May; 135(21):8001-15. PubMed ID: 23641937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crystal structure of human cytochrome P450 2C9 with bound warfarin.
    Williams PA; Cosme J; Ward A; Angove HC; Matak Vinković D; Jhoti H
    Nature; 2003 Jul; 424(6947):464-8. PubMed ID: 12861225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative binding models for CYP2C9 based on benzbromarone analogues.
    Locuson CW; Rock DA; Jones JP
    Biochemistry; 2004 Jun; 43(22):6948-58. PubMed ID: 15170332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
    Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
    Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives.
    Shimada T; Tanaka K; Takenaka S; Murayama N; Martin MV; Foroozesh MK; Yamazaki H; Guengerich FP; Komori M
    Chem Res Toxicol; 2010 Dec; 23(12):1921-35. PubMed ID: 21053930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA.
    Ridderström M; Zamora I; Fjellström O; Andersson TB
    J Med Chem; 2001 Nov; 44(24):4072-81. PubMed ID: 11708911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivatives.
    Locuson CW; Wahlstrom JL; Rock DA; Rock DA; Jones JP
    Drug Metab Dispos; 2003 Jul; 31(7):967-71. PubMed ID: 12814975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation, characterization, and substrate metabolism of gold-immobilized cytochrome P450 2C9.
    Gannett PM; Kabulski J; Perez FA; Liu Z; Lederman D; Locuson CW; Ayscue RR; Thomsen NM; Tracy TS
    J Am Chem Soc; 2006 Jul; 128(26):8374-5. PubMed ID: 16802783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases.
    Huang Q; Liu Q; Yin T; Hu L; Ding H; Liu S; Jiang Y
    Eur J Clin Pharmacol; 2020 Jun; 76(6):833-842. PubMed ID: 32157329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flavonoids diosmetin and hesperetin are potent inhibitors of cytochrome P450 2C9-mediated drug metabolism in vitro.
    Quintieri L; Bortolozzo S; Stragliotto S; Moro S; Pavanetto M; Nassi A; Palatini P; Floreani M
    Drug Metab Pharmacokinet; 2010; 25(5):466-76. PubMed ID: 20877134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study.
    Zhou YH; Zheng QC; Li ZS; Zhang Y; Sun M; Sun CC; Si D; Cai L; Guo Y; Zhou H
    Biochimie; 2006 Oct; 88(10):1457-65. PubMed ID: 16740353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13.
    Guo Y; Wang Y; Si D; Fawcett PJ; Zhong D; Zhou H
    Xenobiotica; 2005 Sep; 35(9):853-61. PubMed ID: 16308280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The substrate binding site of human liver cytochrome P450 2C9: an NMR study.
    Poli-Scaife S; Attias R; Dansette PM; Mansuy D
    Biochemistry; 1997 Oct; 36(42):12672-82. PubMed ID: 9335524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.